---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-114908"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:43:52.180666+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q1 net loss $53.2M; cash $461.7M; taletrectinib PDUFA June 23, 2025

## Summary
- Net loss of $53.2M ($0.16/share) vs $14.8M ($0.07) in Q1 2024; R&D rose to $24.6M, SG&A to $35.4M.
- Cash, equivalents and marketable securities $461.7M as of March 31, 2025.
- FDA Priority Review for taletrectinib NDA on track; PDUFA goal date June 23, 2025.
- Secured up to $250M non-dilutive financing from Sagard Healthcare; $150M royalty and $50M debt upon FDA approval.
- Appointed Stephen Dang, Ph.D., as Senior Vice President, General Counsel in March 2025.

## SEC filing metadata
- accession: 0001193125-25-114908
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/0001193125-25-114908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-114908
- JSON: https://secwatch.observer/filing/0001193125-25-114908.json
- Plain text: https://secwatch.observer/filing/0001193125-25-114908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.